

AUG 28 2007

Urgent
 Confidential
 Action Required
 Reply Requested
 For Your Info.

FAX COVER SHEET

TO: Examiner I. H. Chowdhury
Mail Stop Amendment
Art Unit 1652

LOCATION: USPTO

Fax No.: (571) 273-8300 (Central Facsimile No.)

FROM: Jennifer Haynes
Patent Agent

LOCATION: Genencor Division
Danisco US, Inc.
Legal Department
925 Page Mill Road
Palo Alto, CA 94304-1013
Tel: 650-846-7595
Fax: 650-845-6504

DATE: August 28, 2007

NUMBER OF PAGES TO FOLLOW: 68 SENT BY: klg

Re: Serial No. 10/565,954 Attorney Docket No. GC812-US

Attachments: Transmittal (3 pages) in duplicate, 1449 (1 page) and 1 reference (60 pages).

The original of this facsimile will be sent to you via:

Regular Mail Overnight Mail Hand Delivery Will Not Be Sent


Please initial acknowledgment of receipt by return facsimile _____

NOTE: The information contained in this facsimile message is confidential and may be subject to attorney-client privilege and is intended only for the use of the above named individual(s). If you are not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone (650/846-7500) and return the original transmission to us by mail.

AUG 28 2007

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this communication is being sent by facsimile transmission in accordance with §1.6(d) addressed to Mail Stop: Amendment, No. (571) 273-8300, The Commissioner for Patents, P.O. 1450, Alexandria, VA 22313-1450 on the date shown below.

Date: August 28, 2007By: 

Kay L. Caviglio

PATENT**Docket No. GC812-US****IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of) Group Art Unit: 1652
 Clarkson et al.) Examiner: I. H. Chowdhury, Ph.D.
 Serial No.: 10/565,954)
 Filed: January 26, 2006)
 For: **MODIFIED ENZYMES, METHODS**)
TO PRODUCE MODIFIED)
ENZYMES AND USES)
THEREOF)

Information Disclosure Statement

Mail Stop Amendment
 Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

Sir:

Applicants submit herewith patents, publications or other information (listed on the attached Form PTO-1449 and attached thereto) of which they are aware, that they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR §1.56.

This Information Disclosure Statement:

- (a) accompanies the new patent application submitted herewith. 37 CFR §1.97(a).
- (b) is filed within three months after the filing date of the application or within three months after the date of entry into the national stage of a PCT application as set forth in 37 CFR §1.491.
- (c) as far as is known to the undersigned, is filed before the mailing date of a first Office Action on the merits.

GC812-us IDS trans.

U.S. Serial No. 10/565,954
Page 2

RECEIVED
CENTRAL FAX CENTER

AUG 28 2007

(d) Is filed after the first Office Action and more than three months after the application filing date or PCT national stage date of entry filing but, as far as is known to the undersigned, prior to the mailing date of either a final rejection or a notice of allowance, whichever occurs first, and is accompanied by either the fee (\$180.00) set forth in 37 CFR §1.17(p) or a certification as specified in 37 CFR §1.97(e), as checked below. Authorization to charge Deposit Account No. 07-1048 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement is provided in the Transmittal Letter submitted herewith in duplicate.

(e) is filed after the mailing date of either a final rejection or a notice of allowance, whichever occurred first, and is accompanied by authorization (in the Transmittal Letter submitted herewith in duplicate) to charge Deposit Account No. 07-1048 the fee (\$180.00) set forth in 37 CFR §1.17(l)(1) and a certification as specified in 37 CFR §1.97(e), as checked below. **This document is to be considered as a petition requesting consideration of the Supplemental Information Disclosure Statement.**

[If either of boxes (d) or (e) is checked above, the following "certification" under 37 CFR §1.97(e) may need to be completed.] The undersigned certifies that:

- Each item of information contained in the Information Disclosure Statement was cited in a communication mailed from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.
- No item of information contained in this Information Disclosure Statement was cited in a communication mailed from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

A concise explanation of relevance of the items listed on PTO-1449 is:

- not given
- given for each listed item
- given for only non-English language listed item(s)
- in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references.

U.S. Serial No. 10/565,954
Page 3


The Examiner is reminded that a "concise explanation of the relevance" of the submitted prior art "may be nothing more than identification of the particular figure or paragraph of the patent or publication which has some relation to the claimed invention." MPEP §609.

While the information and references disclosed in this Information Disclosure Statement may be "material" pursuant to 37 CFR §1.56, it is not intended to constitute an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

In accordance with 37 CFR §1.97(b), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR §1.56(a) exists. It is submitted that the Information Disclosure Statement is in compliance with 37 CFR §1.98 and MPEP §609 and the Examiner is respectfully requested to consider the listed references.

The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16 and 1.17 that may be required, or credit any overpayment to Deposit Account No. 07-1048, referencing Attorney Docket No. GC812-US. A duplicate of this paper is enclosed.

Respectfully submitted,



Jennifer A. Haynes, Ph.D.
Agent for Applicants
Registration No. 48,868

Date: August 28, 2007

Genencor Division, Danisco US, Inc.
925 Page Mill Road
Palo Alto, CA 94304
Tel. 650-846-7595
Fax: 650-845-6504

812-us IDS trans

INFORMATION DISCLOSURE CITATION

INFORMATION DISCLOSURE CITATION	
Attorney Docket No.: GC812-US	Serial No.: 10/565,954
Applicant: Clarkson et al.	
Filing Date: July 31, 2006	Group: 1652
Page <u>1</u> of <u>1</u>	Date of this Submission: August 28, 2007

US PATENT DOCUMENTS

Examiner's Initial	Document Number	Date	Name	Class	Sub- Class	Filing Date

FOREIGN PATENT DOCUMENTS

Examiner's Initials	Document Number	Date	Country	Class	Sub- Class	Translation Yes/No
	1 131 447 B1	11/16/99	EP			

OTHER DOCUMENTS

Examiner	Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not

considered. Include copy of this form with next communication to applicant.
PTO-1449